Image Source: AsiaOne
AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of NeuroblastomaAUM302 has potential to be the first multi-kinase inhibitor class of drug in NeuroblastomaGlobeNewswireNovember 30, 2022SINGAPORE and BETHESDA, Md., Nov. 30, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences Pte. Ltd. (“AUM”), a global clinical-stage biotech company focused on discovering and developing precision oncology therapeutics, announced today that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation for AUM302, a potential first-in-class oral kinase inhibitor that targets not only PI3K, but also key resistance mechanisms such as PIM and mTOR, for the treatment of neuroblastoma.
Source: AsiaOne